Sugi Predict

Sugi Predict / Targets / GRK2

GRK2

Beta-adrenergic receptor kinase 1 · P25098 · GRK2 on Sugi Atlas →

24,099 patent compounds predicted against GRK2, 15,181 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1273795 SCHEMBL1273795 1.00 11/20
SCHEMBL1273753 SCHEMBL1273753 1.00 10/20
SCHEMBL1273784 SCHEMBL1273784 1.00 9/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL660282) 0.58 9/20
SCHEMBL690272 SCHEMBL690272 0.65 8/20
SCHEMBL690273 SCHEMBL690273 0.65 8/20
SCHEMBL1273020 SCHEMBL1273020 1.00 7/20
SCHEMBL986477 SCHEMBL986477 0.49 7/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL659478) 0.58 6/20
SCHEMBL982736 SCHEMBL982736 0.53 6/20
SCHEMBL992230 SCHEMBL992230 0.58 5/20
SCHEMBL983243 SCHEMBL983243 0.54 5/20
SCHEMBL986491 SCHEMBL986491 0.51 5/20
SCHEMBL858894 SCHEMBL858894 0.49 5/20
SCHEMBL544248 SCHEMBL544248 0.47 5/20
Paroxetine Paroxetine (SCHEMBL27799) 1.00 4/20
Paroxetine Paroxetine (SCHEMBL114238) 1.00 4/20
Paroxetine Paroxetine (SCHEMBL145267) 1.00 4/20
Paroxetine Paroxetine (SCHEMBL145268) 1.00 4/20
Paroxetine Paroxetine (SCHEMBL33348) 0.98 4/20

Clinical trials — most relevant to GRK2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Intraoperative Infusion of Precedex to Reduce Length of Stay After Lumbar Spine Fusion PHASE4COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer PHASE3COMPLETED
Paroxetine-mediated GRK2 Inhibition to Reduce Cardiac Remodeling After Acute Myocardial Infarction PHASE2COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin PHASE2UNKNOWN
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old PHASE2ACTIVE_NOT_RECRUITING
Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma PHASE1/PHASE2COMPLETED
Dose Ranging Study of Carbidopa-levodopa PHASE2COMPLETED
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma PHASE2UNKNOWN
Effect of Gene Variants on Dopamine Receptor Natriuretic Responses PHASE1UNKNOWN
Brain Imaging, Genetics and Treatment for Major Depression PHASE1WITHDRAWN
Remote Ischaemic Conditioning in Endovascular Recanalization for Proximal Anterior Circulation Occlusion Study PHASE1UNKNOWN
Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer PHASE1COMPLETED
SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis EARLY_PHASE1UNKNOWN
Measuring G Protein-coupled Receptor Kinase-2 (GRK2) in the Blood to Diagnose and Treat Patients With Heart Failure nanCOMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus nanUNKNOWN
Genetic Variants Associated With Adolescent Suicide Attempts nanCOMPLETED
Effect of Dietary Oils as G-protein-coupled Receptor Agonists on Glucose Tolerance nanUNKNOWN
Genetic Predictors of Lithium Response in Bipolar Disorder nanCOMPLETED
Adrenocorticotropic Hormone (ACTH) Stimulation and G Protein nanCOMPLETED
Effects of a Multiple Sclerosis Relapse Therapy on Offspring Neurocognitive Development and Behaviour nanUNKNOWN
Brain Receptors in Sympathetic Nervous System Regulation nanCOMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia nanUNKNOWN
Acamprosate: Genes Associated With Response nanCOMPLETED
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease nanCOMPLETED
Mass Balance Study of [14C]Chiauranib nanCOMPLETED
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients nanUNKNOWN
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction nanCOMPLETED
The Application of 68Ga-Pentixafor Alongside 68Ga-FAPI-04 PET/MR for Assessing Primary Aldosteronism. nanNOT_YET_RECRUITING
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a GRK2 binder may also engage these)

ProteinNameSimilarity
Q64682 — 1.000 Q64682 →
P26817 — 1.000 P26817 →
O97627 — 1.000 O97627 →
Q99MK8 — 1.000 Q99MK8 →
P21146 — 1.000 P21146 →
Q3UYH7 — 1.000 Q3UYH7 →
Q09639 — 1.000 Q09639 →
P26818 — 0.998 P26818 →
P26819 — 0.998 P26819 →
GRK3 G protein-coupled receptor kinase 3 0.998 landscape →
P32865 — 0.994 P32865 →
O19111 — 0.992 O19111 →
Q66JF3 — 0.991 Q66JF3 →
Q02956 — 0.991 Q02956 →
Q5R4K9 — 0.990 Q5R4K9 →
O08605 — 0.990 O08605 →
Q755C4 — 0.990 Q755C4 →
PRKCZ Protein kinase C zeta type 0.990 landscape →
Q9ZUZ2 — 0.990 Q9ZUZ2 →
P51138 — 0.990 P51138 →
Q90XF2 — 0.990 Q90XF2 →
Q19266 — 0.990 Q19266 →
Q62074 — 0.990 Q62074 →
Q8VZD5 — 0.990 Q8VZD5 →
O12990 — 0.990 O12990 →
A8WUG4 — 0.990 A8WUG4 →
F1M7Y5 — 0.989 F1M7Y5 →
Q66I46 — 0.989 Q66I46 →
Q8BRK8 — 0.989 Q8BRK8 →
Q9NPF8 — 0.989 Q9NPF8 →